Head-To-Head Comparison: Corium International (CORI) and BioLife Solutions (BLFS)
Corium International (NASDAQ: CORI) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings.
This is a breakdown of recent recommendations and price targets for Corium International and BioLife Solutions, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Corium International presently has a consensus target price of $12.33, suggesting a potential upside of 36.58%. BioLife Solutions has a consensus target price of $5.50, suggesting a potential upside of 16.28%. Given Corium International’s higher probable upside, equities research analysts clearly believe Corium International is more favorable than BioLife Solutions.
Valuation and Earnings
This table compares Corium International and BioLife Solutions’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Corium International||$30.34 million||10.64||-$34.21 million||($1.73)||-5.22|
|BioLife Solutions||$9.31 million||6.72||-$2.21 million||($0.47)||-10.06|
BioLife Solutions has higher revenue, but lower earnings than Corium International. BioLife Solutions is trading at a lower price-to-earnings ratio than Corium International, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Corium International has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500.
This table compares Corium International and BioLife Solutions’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
90.1% of Corium International shares are owned by institutional investors. Comparatively, 2.6% of BioLife Solutions shares are owned by institutional investors. 45.7% of Corium International shares are owned by company insiders. Comparatively, 37.7% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Corium International beats BioLife Solutions on 7 of the 12 factors compared between the two stocks.
Corium International Company Profile
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
BioLife Solutions Company Profile
BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.
Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.